Rezultate t\u00eb jasht\u00ebzakonshme ka arritur nj\u00eb studimi \u201ci paprecedent\u00eb\u201d q\u00eb tregon se nj\u00eb injeksion kund\u00ebr kancerit me veprim t\u00eb trefisht\u00eb mund t\u00eb zhduk\u00eb t\u00eb gjitha tumoret tek pacient\u00ebt.<\/p>\n
N\u00eb nj\u00eb studim nd\u00ebrkomb\u00ebtar q\u00eb p\u00ebrfshin 11 vende, injeksioni iu ofrua pacient\u00ebve, kanceri i t\u00eb cil\u00ebve ishte p\u00ebrhapur ose ishte rikthyer dhe s\u00ebmundja e t\u00eb cil\u00ebve nuk kishte arritur t’i p\u00ebrgjigjej trajtimeve t\u00eb tjera, raporton The Guardian, transmeton Periskopi.<\/p>\n
Injeksioni, i quajtur “amivantamab”, tkurri tumoret e m\u00eb shum\u00eb se nj\u00eb t\u00eb tret\u00ebs s\u00eb pacient\u00ebve, me ndryshime dramatike t\u00eb v\u00ebrejtura brenda disa jav\u00ebsh. N\u00eb 15 prej tyre, mjek\u00ebt zbuluan se ila\u00e7i i kishte shkat\u00ebrruar plot\u00ebsisht tumoret e tyre.<\/p>\n
Kevin Harrington, profesor n\u00eb terapit\u00eb biologjike t\u00eb kancerit n\u00eb Institutin e K\u00ebrkimeve t\u00eb Kancerit, Lond\u00ebr (ICR), tha: \u201cK\u00ebto jan\u00eb p\u00ebrgjigje t\u00eb forta t\u00eb paprecedent\u00eb tek pacient\u00ebt, s\u00ebmundja e t\u00eb cil\u00ebve \u00ebsht\u00eb b\u00ebr\u00eb rezistente si ndaj kimioterapis\u00eb ashtu edhe ndaj imunoterapis\u00eb.”<\/p>\n
\u201cKy \u00ebsht\u00eb nj\u00eb grup pacient\u00ebsh p\u00ebr t\u00eb cil\u00ebt opsionet e trajtimit jan\u00eb jasht\u00ebzakonisht t\u00eb kufizuara, k\u00ebshtu q\u00eb t\u00eb shoh\u00ebsh k\u00ebt\u00eb nivel p\u00ebrfitimi \u00ebsht\u00eb shum\u00eb e habitshme.\u201d<\/p>\n
Harrington, gjithashtu nj\u00eb onkolog konsulent n\u00eb fondacionin Royal Marsden NHS, shtoi: \u201cKy trajtim ka potencialin t\u00eb p\u00ebrfitoj\u00eb mij\u00ebra pacient\u00eb \u00e7do vit.\u201d<\/p>\n
Rezultatet do t\u00eb prezantohen t\u00eb diel\u00ebn n\u00eb \u00c7ikago n\u00eb konferenc\u00ebn m\u00eb t\u00eb madhe bot\u00ebrore p\u00ebr kancerin, takimin vjetor t\u00eb Shoqat\u00ebs Amerikane t\u00eb Onkologjis\u00eb Klinike (Asco).<\/p>\n
N\u00eb prov\u00eb, 102 pacient\u00eb me kancer t\u00eb kok\u00ebs dhe qaf\u00ebs, kanceri i gjasht\u00eb m\u00eb i zakonsh\u00ebm n\u00eb bot\u00eb, iu dha injeksioni. Tumoret u tkurr\u00ebn ose u zhduk\u00ebn plot\u00ebsisht te 43 pacient\u00eb, p\u00ebrfshir\u00eb 28 tumoret e t\u00eb cil\u00ebve u tkurr\u00ebn ndjesh\u00ebm dhe 15 q\u00eb i pan\u00eb ato t\u00eb zhdukura plot\u00ebsisht.<\/p>\n
Hulumtuesit than\u00eb se injeksioni kishte treguar gjithashtu rezultate t\u00eb ngjashme te pacient\u00ebt me kancer t\u00eb mushk\u00ebrive. “Amivantamabi”, i zhvilluar nga “Johnson & Johnson”, tani po vler\u00ebsohet n\u00eb rreth 60 prova klinike, kryesisht p\u00ebr kancerin e mushk\u00ebrive, por edhe p\u00ebr kancerin kolorektal, t\u00eb trurit dhe t\u00eb stomakut.<\/p>\n
Injeksioni inteligjent synon kancerin n\u00eb tre m\u00ebnyra. Ai bllokon si EGFR (receptori i faktorit t\u00eb rritjes epidermale), nj\u00eb protein\u00eb q\u00eb ndihmon tumoret t\u00eb rriten, ashtu edhe MET, nj\u00eb rrug\u00eb q\u00eb qelizat kancerogjene shpesh e p\u00ebrdorin p\u00ebr t’i shp\u00ebtuar trajtimit. Ai gjithashtu ndihmon n\u00eb aktivizimin e sistemit imunitar p\u00ebr t\u00eb sulmuar tumorin.<\/p>\n
Nj\u00eb nga pacient\u00ebt e par\u00eb q\u00eb p\u00ebrfitoi ishte Carl Walsh, 56 vje\u00e7, i cili u diagnostikua me kancer t\u00eb gjuh\u00ebs n\u00eb vitin Maj 2024 dhe u bashkua me prov\u00ebn OrigAMI-4 n\u00eb Royal Marsden n\u00eb korrik 2025.<\/p>\n
\u201cFillimisht u trajtova si me kimioterapi ashtu edhe me imunoterapi, t\u00eb cilat p\u00ebr fat t\u00eb keq nuk pat\u00ebn sukses,\u201d tha ai.<\/p>\n
\u201cN\u00eb at\u00eb pik\u00eb, m\u00eb rekomanduan p\u00ebr prov\u00ebn OrigAMI-4. Tani jam n\u00eb ciklin tim t\u00eb 17-t\u00eb t\u00eb trajtimit dhe jam shum\u00eb i k\u00ebnaqur me progresin deri m\u00eb tani.\u201d<\/p>\n
Ndryshe nga shum\u00eb trajtime p\u00ebr kancerin, “amivantamabi” jepet si nj\u00eb doz\u00eb e vog\u00ebl n\u00ebn l\u00ebkur\u00eb n\u00eb vend t\u00eb nj\u00eb injeksioni intravenoz, duke e b\u00ebr\u00eb trajtimin m\u00eb t\u00eb shpejt\u00eb dhe m\u00eb t\u00eb p\u00ebrshtatsh\u00ebm p\u00ebr pacient\u00ebt dhe shum\u00eb m\u00eb t\u00eb leht\u00eb p\u00ebr t’u kryer n\u00eb klinikat ambulatore.<\/p>\n
Shumica e efekteve an\u00ebsore t\u00eb trajtimit, t\u00eb dh\u00ebna nj\u00eb her\u00eb n\u00eb tre jav\u00eb, ishin t\u00eb lehta deri n\u00eb t\u00eb moderuara, me m\u00eb pak se nj\u00eb n\u00eb 10 pacient\u00eb t\u00eb detyruar t\u00eb nd\u00ebrpresin trajtimin e tyre.<\/p>\n
Walsh, nga Birmingham, tha: \u201cTani ndihem i aft\u00eb t\u00eb jetoj nj\u00eb jet\u00eb normale. Para se t\u00eb filloja prov\u00ebn, kisha v\u00ebshtir\u00ebsi t\u00eb flisja si\u00e7 duhet dhe e kisha t\u00eb v\u00ebshtir\u00eb t\u00eb haja p\u00ebr shkak t\u00eb \u00ebnjtjes dhe dhimbjes.<\/p>\n
\u201cQ\u00eb nga fillimi i trajtimit, \u00ebnjtja \u00ebsht\u00eb zvog\u00ebluar ndjesh\u00ebm dhe nivelet e dhimbjes sime jan\u00eb p\u00ebrmir\u00ebsuar ndjesh\u00ebm. Gjithashtu, nuk po p\u00ebrjetoj m\u00eb t\u00eb nj\u00ebjtat efekte an\u00ebsore q\u00eb ndikojn\u00eb n\u00eb jet\u00eb q\u00eb kisha gjat\u00eb kimioterapis\u00eb.\u201d<\/p>\n
Ai shtoi: \u201cKur gj\u00ebrat ishin n\u00eb gjendjen e tyre m\u00eb t\u00eb keqe, haja sup\u00eb, puding orizi, kana\u00e7e me ravioli dhe spageti dhe shum\u00eb, shum\u00eb om\u00ebleta, t\u00eb gjitha t\u00eb shtuara nga tre pije qum\u00ebshti ushqyese t\u00eb p\u00ebrshkruara n\u00eb dit\u00eb. Humba goxha pesh\u00eb.<\/p>\n
\u201cPas vet\u00ebm dy cikleve t\u00eb trajtimit, dieta ime filloi t\u00eb kthehej n\u00eb normale dhe po haja nj\u00eb diet\u00eb t\u00eb plot\u00eb pas gjasht\u00eb muajsh. Gj\u00ebja q\u00eb m\u00eb p\u00eblqeu m\u00eb shum\u00eb ishte bifteku i par\u00eb i madh. T\u00eb folurit tim \u00ebsht\u00eb kthyer plot\u00ebsisht n\u00eb normalitet dhe n\u00eb pun\u00eb flas rregullisht me kufje pa probleme.\u201d<\/p>\n
Studiuesit theksuan gjithashtu se studimi u p\u00ebrqendrua te njer\u00ebzit me kancer t\u00eb kok\u00ebs dhe qaf\u00ebs, ku nuk p\u00ebrfshiheshin ata me karcinom\u00eb qelizore skuamoze orofaringeale pozitive ndaj virusit t\u00eb papillomave njer\u00ebzore (HPV). Kjo \u00ebsht\u00eb ve\u00e7an\u00ebrisht e r\u00ebnd\u00ebsishme, than\u00eb ata, pasi kanceret e kok\u00ebs dhe qaf\u00ebs q\u00eb nuk shkaktohen nga HPV zakonisht jan\u00eb m\u00eb t\u00eb v\u00ebshtira p\u00ebr t’u trajtuar, duke e b\u00ebr\u00eb p\u00ebrparimin n\u00eb k\u00ebt\u00eb grup jasht\u00ebzakonisht t\u00eb r\u00ebnd\u00ebsish\u00ebm.<\/p>\n
Pacient\u00ebt q\u00eb marrin “amivantamab” jetuan mesatarisht 12.5 muaj n\u00eb p\u00ebrgjith\u00ebsi pas fillimit t\u00eb trajtimit, pavar\u00ebsisht se kishin nj\u00eb form\u00eb kanceri me rezultate shum\u00eb t\u00eb dob\u00ebta, pasi trajtimet standarde ndalojn\u00eb s\u00eb funksionuari.<\/p>\n
Prof. Kristian Helin, drejtori ekzekutiv i ICR, tha: “Ky studim tregon se si zhvillimi i trajtimeve t\u00eb reja p\u00ebrmes k\u00ebrkimit rigoroz t\u00eb kancerit mund t\u00eb \u00e7oj\u00eb n\u00eb p\u00ebrparime dometh\u00ebn\u00ebse, madje edhe p\u00ebr pacient\u00ebt me mund\u00ebsi trajtimi shum\u00eb t\u00eb kufizuara.”<\/p>\n
“Arritja e k\u00ebtij niveli t\u00eb p\u00ebrgjigjes s\u00eb tumorit dhe inkurajimi i rezultateve t\u00eb mbijetes\u00ebs n\u00eb nj\u00eb grup kaq sfidues p\u00ebr t’u trajtuar p\u00ebrfaq\u00ebson nj\u00eb hap t\u00eb r\u00ebnd\u00ebsish\u00ebm p\u00ebrpara.”, tha ai.<\/p>\n","protected":false},"excerpt":{"rendered":"
Rezultate t\u00eb jasht\u00ebzakonshme ka arritur nj\u00eb studimi \u201ci paprecedent\u00eb\u201d q\u00eb tregon se nj\u00eb injeksion kund\u00ebr kancerit me veprim t\u00eb trefisht\u00eb mund t\u00eb zhduk\u00eb t\u00eb gjitha tumoret tek pacient\u00ebt. N\u00eb nj\u00eb studim nd\u00ebrkomb\u00ebtar q\u00eb p\u00ebrfshin 11 vende, injeksioni iu ofrua pacient\u00ebve, kanceri i t\u00eb cil\u00ebve ishte p\u00ebrhapur ose ishte rikthyer dhe s\u00ebmundja e t\u00eb cil\u00ebve nuk […]<\/p>\n","protected":false},"author":1,"featured_media":235101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-235100","post","type-post","status-publish","format-standard","has-post-thumbnail","category-shendetesi"],"_links":{"self":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts\/235100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/comments?post=235100"}],"version-history":[{"count":1,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts\/235100\/revisions"}],"predecessor-version":[{"id":235102,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/posts\/235100\/revisions\/235102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/media\/235101"}],"wp:attachment":[{"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/media?parent=235100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/categories?post=235100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/radiostargjilan.com\/web\/wp-json\/wp\/v2\/tags?post=235100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}